Basiliximab
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD25 |
Clinical data | |
Trade names | Simulect |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 7.2 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C6378H9844N1698O1997S48 |
Molar mass | 143801.68 g·mol−1 |
(what is this?) (verify) |
Uses
Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2]
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]
History
It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[5]
See also
References and notes
- MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
- Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
- Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.
- Basiliximab label
- Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.